Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patients who receive reduced dose chemotherapy in combination with immunotherapy.

Trial Details

NCT ID

NCT06731413

Phase

PHASE2

Sponsor

Virginia Commonwealth University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Reduced Dose of Chemotherapy and Immunotherapy

Locations (sample)

Richmond, Virginia, United States|37.55376,-77.46026
Tappahannock, Virginia, United States|37.92541,-76.85913

Key Eligibility Criteria

Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) (either squamous or non- squamous)
Stage IIIB, IIIC or IV disease OR have recurrent disease and not be candidates for curative treatment such as combined chemo-radiation
No previous line of treatment in the recurrent or metastatic setting. Neoadjuvant or adjuvant treatment more than 6 months before enrollment is acc…
Age 70 or meeting frailty definition or above at the date of signing informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →